Asset Details
Do you wish to reserve the book?
The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle
Do you wish to request the book?
The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The CRH1 Antagonist GSK561679 Increases Human Fear But Not Anxiety as Assessed by Startle
2015
Overview
Fear to predictable threat and anxiety to unpredictable threat reflect distinct processes mediated by different brain structures, the central nucleus of the amygdala and the bed nucleus of the stria terminalis (BNST), respectively. This study tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK561679 differentially reduces anxiety but increases fear in humans. A total of 31 healthy females received each of four treatments: placebo, 50 mg GSK561679 (low-GSK), 400 mg GSK561679 (high-GSK), and 1 mg alprazolam in a crossover design. Participants were exposed to three conditions during each of the four treatments. The three conditions included one in which predictable aversive shocks were signaled by a cue, a second during which shocks were administered unpredictably, and a third condition without shock. Fear and anxiety were assessed using the acoustic startle reflex. High-GSK had no effect on startle potentiation during unpredictable threat (anxiety) but increased startle potentiation during the predictable condition (fear). Low-GSK did not affect startle potentiation across conditions. Consistent with previous findings, alprazolam reduced startle potentiation during unpredictable threat but not during predictable threat. The increased fear by high-GSK replicates animal findings and suggests a lift of the inhibitory effect of the BNST on the amygdala by the CRF1 antagonist.
Publisher
Nature Publishing Group
Subject
/ Adult
/ Anti-Anxiety Agents - pharmacology
/ Anticipation, Psychological - physiology
/ Anxiety - chemically induced
/ Azabicyclo Compounds - adverse effects
/ Azabicyclo Compounds - pharmacology
/ Dose-Response Relationship, Drug
/ Female
/ Humans
/ Original
/ Oxadiazoles - adverse effects
/ Psychotropic Drugs - adverse effects
/ Psychotropic Drugs - pharmacology
/ Receptors, Corticotropin-Releasing Hormone - antagonists & inhibitors
/ Receptors, Corticotropin-Releasing Hormone - metabolism
/ Reflex, Startle - drug effects
/ Reflex, Startle - physiology
/ Threats
